Use access key #2 to skip to page content.
$0.84 0.08 (10.53%)
7/8/2008 3:59 PM

Generex Biotechnology Corp (GNBT)

CAPS Rating:
***

The Company is engaged primarily in the research, development and commercialization of drug delivery systems and technologies.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

GNBT doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

202 Outperforms
12 Underperforms
 

All-Stars

24 Outperforms
4 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Players bullish on GNBT are also bullish on:

Players bearish on GNBT are also bearish on:

Ticker Tags

Canada (55), Biotechnology (293), Micro Cap (4824), Ontario (8), Bird Flu (8), Diversified Communication Services (56), Drug Delivery (22)
Suggest a tag

Generex Biotechnology Corp At A Glance

Current Price: $0.84
Last Trade Time: 7/8/2008 3:59 PM
Open: $0.76
Previous Close: $0.76
Daily Range: $0.76 - $0.85
52-Week Range: $0.74 - $1.95
Volume: 554,343
Market Cap: $85.26M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

GNBT VS S&P 500 (SPY)

GNBT 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for GNBT

More Headlines...

Top Bull Pitch

Recs

2

Generex Biotechnology Corp (GNBT)

Avatar boyplanner (20.02) Submitted: 12/06/07 2:30 PM

Diabetes prevention/care is a billion dollar industry, and depending upon FDA approval, GNBT has unlimited growth potential.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

Generex Biotechnology Corp (GNBT)

Avatar pobeda1 (< 20) Submitted: 10/23/06 6:07 AM

Incompetent management. Achieved virtually nothing in the past 10 years. Extremely poor fundamentals. Conduct unconventional clinical trials to avoid FDA pathway.

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 55 :   1 2 3 4 5 Next » Jump to page:

Recs

1

 (GNBT)

Avatar Voyt608 (< 20) Submitted: 1/07/08 9:51 PM : Outperform Start Price: $1.59 GNBT Score: -36.70

GNBT's Oral insulin delivery system is a significant advancement in the treatment of Diabetes Mellitus and will be soon approved for use in the USA. It will be a cash cow, funding the companies cancer treatment programs for the foreseeable future.


I expect GNBT to be a blockbuster stock.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GNBT)

Avatar Biotech2008 (71.15) Submitted: 1/04/08 10:08 PM : Outperform Start Price: $1.64 GNBT Score: -38.48

jpg101 @5.53

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GNBT)

Avatar edjab (< 20) Submitted: 1/02/08 9:37 AM : Outperform Start Price: $1.65 GNBT Score: -35.77

Good potential. desired remedy. easy medication control for diabetes & others.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (GNBT)

Avatar rand700 (< 20) Submitted: 12/24/07 3:37 PM : Outperform Start Price: $1.74 GNBT Score: -37.29

GNBT is one of the few companies that is making insulin that is deliverable by the oral route, the advantages of generex's product is that it's delivered via the mucous membrane of the mouth,rather then inhaled and absorbed by the lung as other oral insulin makers, the latter deliver method has a number of disadvantages including variable absorption and problems in patients with lung disease.
generex also holds a number of patents based on antigen treatment via mucous membrane absorption to treat a variety of infectious or carcinomatous diseases- these are in the development phase, if successful the company would have significant gains.
this companies insulin product hasn't been approved in the US yet- it has been approved in ecuador and recently in india-

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GNBT)

Avatar drummerboy1985 (69.58) Submitted: 12/13/07 6:04 PM : Outperform Start Price: $1.81 GNBT Score: -39.58

I have owned stock in the company for about a year now and have watched it rise big and then fall big. They have a new delivery method for drugs through an inhaler that I think will be a big hit though.





Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 55 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackRodmanRen < 20 06/13/07 06/13/07 Outperform NS $1.89-55.56%-15.48%-40.07

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners